140 related articles for article (PubMed ID: 9525721)
21. Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues.
Butler M; Stecker K; Bennett CF
Lab Invest; 1997 Oct; 77(4):379-88. PubMed ID: 9354772
[TBL] [Abstract][Full Text] [Related]
22. Antisense oligodeoxyribonucleotides: stability and distribution after intracerebral injection into rat brain.
Szklarczyk A; Kaczmarek L
J Neurosci Methods; 1995 Aug; 60(1-2):181-7. PubMed ID: 8544478
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1.
Zhang R; Diasio RB; Lu Z; Liu T; Jiang Z; Galbraith WM; Agrawal S
Biochem Pharmacol; 1995 Mar; 49(7):929-39. PubMed ID: 7741765
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice.
Saijo Y; Perlaky L; Wang H; Busch H
Oncol Res; 1994; 6(6):243-9. PubMed ID: 7865900
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of antisense analogues in the central nervous system.
Szklarczyk A; Kaczmarek L
Neurochem Int; 1997 Sep; 31(3):413-23. PubMed ID: 9246683
[TBL] [Abstract][Full Text] [Related]
26. In vivo stability, disposition and metabolism of a "hybrid" oligonucleotide phosphorothioate in rats.
Zhang R; Lu Z; Zhao H; Zhang X; Diasio RB; Habus I; Jiang Z; Iyer RP; Yu D; Agrawal S
Biochem Pharmacol; 1995 Aug; 50(4):545-56. PubMed ID: 7646561
[TBL] [Abstract][Full Text] [Related]
27. Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS.
Boado RJ; Tsukamoto H; Pardridge WM
J Pharm Sci; 1998 Nov; 87(11):1308-15. PubMed ID: 9811482
[TBL] [Abstract][Full Text] [Related]
28. Topical and intravitreous administration of cationic nanoemulsions to deliver antisense oligonucleotides directed towards VEGF KDR receptors to the eye.
Hagigit T; Abdulrazik M; Orucov F; Valamanesh F; Hagedorn M; Lambert G; Behar-Cohen F; Benita S
J Control Release; 2010 Aug; 145(3):297-305. PubMed ID: 20420865
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration.
Phillips JA; Craig SJ; Bayley D; Christian RA; Geary R; Nicklin PL
Biochem Pharmacol; 1997 Sep; 54(6):657-68. PubMed ID: 9310342
[TBL] [Abstract][Full Text] [Related]
30. Distribution of phosphodiester and phosphorothioate oligonucleotides in rat brain after intraventricular and intrahippocampal administration determined by in situ hybridization.
Yaida Y; Nowak TS
Regul Pept; 1995 Oct; 59(2):193-9. PubMed ID: 8584754
[TBL] [Abstract][Full Text] [Related]
31. Spinal distribution and metabolism of 2'-O-(2-methoxyethyl)-modified oligonucleotides after intrathecal administration in rats.
Butler M; Hayes CS; Chappell A; Murray SF; Yaksh TL; Hua XY
Neuroscience; 2005; 131(3):705-15. PubMed ID: 15730875
[TBL] [Abstract][Full Text] [Related]
32. Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration.
Agrawal S; Zhang X; Lu Z; Zhao H; Tamburin JM; Yan J; Cai H; Diasio RB; Habus I; Jiang Z
Biochem Pharmacol; 1995 Aug; 50(4):571-6. PubMed ID: 7646565
[TBL] [Abstract][Full Text] [Related]
33. Use of a simple fractionation method to evaluate binding, internalization and intracellular distribution of oligonucleotides in vascular smooth muscle cells.
Eboue D; Auger R; Angiari C; Le Doan T; Tenu JP
Arch Physiol Biochem; 2003 Jul; 111(3):265-72. PubMed ID: 14972750
[TBL] [Abstract][Full Text] [Related]
34. In vivo pharmacokinetics of phosphorothioate oligonucleotides containing contiguous guanosines.
Agrawal S; Tan W; Cai Q; Xie X; Zhang R
Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):245-9. PubMed ID: 9212919
[No Abstract] [Full Text] [Related]
35. Pharmacology and toxicology of phosphorothioate oligonucleotides in the mouse, rat, monkey and man.
Iversen PL; Copple BL; Tewary HK
Toxicol Lett; 1995 Dec; 82-83():425-30. PubMed ID: 8597088
[TBL] [Abstract][Full Text] [Related]
36. In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration.
Graham MJ; Crooke ST; Monteith DK; Cooper SR; Lemonidis KM; Stecker KK; Martin MJ; Crooke RM
J Pharmacol Exp Ther; 1998 Jul; 286(1):447-58. PubMed ID: 9655890
[TBL] [Abstract][Full Text] [Related]
37. Studies on the mechanism of stabilization of partially phosphorothioated oligonucleotides against nucleolytic degradation.
Uhlmann E; Ryte A; Peyman A
Antisense Nucleic Acid Drug Dev; 1997 Aug; 7(4):345-50. PubMed ID: 9303186
[TBL] [Abstract][Full Text] [Related]
38. Sequence dependency of the internalization and distribution of phosphorothioate oligonucleotides in vascular smooth muscle cells.
Etore F; Tenu JP; Teiger E; Adnot S; Lonchampt MO; Pirotzki E; Le Doan T
Biochem Pharmacol; 1998 May; 55(9):1465-73. PubMed ID: 10076539
[TBL] [Abstract][Full Text] [Related]
39. Bolus intravenous injection of phosphorothioate oligonucleotides causes hypotension by acting as alpha(1)-adrenergic receptor antagonists.
Iversen PL; Cornish KG; Iversen LJ; Mata JE; Bylund DB
Toxicol Appl Pharmacol; 1999 Nov; 160(3):289-96. PubMed ID: 10544063
[TBL] [Abstract][Full Text] [Related]
40. Maternal and fetal distribution of a phosphorothioate oligonucleotide in rats after intravenous infusion.
Soucy NV; Riley JP; Templin MV; Geary R; de Peyster A; Levin AA
Birth Defects Res B Dev Reprod Toxicol; 2006 Feb; 77(1):22-8. PubMed ID: 16496297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
